its all about retail and some tute selling. If anything the shorts have provided a cushing as they bought to cover as this dog spiked down into the $16/17 range. JM & Co have done a suck out loud job of managing expectations. Cash burn is the only other meaningfull indication for any small biotech and given alnylam's cash position its meaningless.